Search research articles
Contact Us
Filters
Showing results (21-30 of 42) with videos related to
Page
of 5
Sort By:
Journal of Clinical Microbiology
|
March 20, 2015
Has CXCL13 an added value in diagnosis of neurosyphilis?
Khutso M Mothapo, Marcel M Verbeek, Lieven B van der Velden, et al.
AIDS (London, England)
|
November 13, 2015
Safety of rilpivirine and boceprevir coadministration in HIV-infected patients treated for acute hepatitis C virus infection
Sebastiaan J Hullegie, Brenda C M de Winter, Dirk Posthouwer, et al.
Brain Imaging and Behavior
|
October 17, 2016
Resting-state subcortical functional connectivity in HIV-infected patients on long-term cART
Marloes A M Janssen, Max Hinne, Ronald J Janssen, et al.
AIDS (London, England)
|
June 6, 2008
Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications
Carolien J P Beukel van den Bout-van den, Marjolein E W Bosch, David M Burger, et al.
Antiviral Therapy
|
December 3, 2003
A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study)
David M Burger, Rob E Aarnoutse, Jeanne P Dieleman, et al.
Antimicrobial Agents and Chemotherapy
|
September 12, 2007
Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects
Manon J van der Lee, Audrey A M Blenke, Gerard A Rongen, et al.
Drug Metabolism Reviews
|
August 1, 2006
Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents
Carolien J P van den Bout-van den Beukel, Peter P Koopmans, André J A M van der Ven, et al.
AIDS (London, England)
|
June 17, 2005
Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications
Charles J L la Porte, Emile F Schippers, Marchina E van der Ende, et al.
Clinical Pharmacology and Therapeutics
|
February 2, 2002
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers
Rob E Aarnoutse, Karin J T Grintjes, Denise S C Telgt, et al.
AIDS (London, England)
|
May 6, 2008
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets
Hanneke M J Nijland, Rafaëlla F A L'homme, Gerard A Rongen, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 42) with videos related to
Sort By:
Page
of 5
Journal of Clinical Microbiology
|
March 20, 2015
Has CXCL13 an added value in diagnosis of neurosyphilis?
Khutso M Mothapo, Marcel M Verbeek, Lieven B van der Velden, et al.
AIDS (London, England)
|
November 13, 2015
Safety of rilpivirine and boceprevir coadministration in HIV-infected patients treated for acute hepatitis C virus infection
Sebastiaan J Hullegie, Brenda C M de Winter, Dirk Posthouwer, et al.
Brain Imaging and Behavior
|
October 17, 2016
Resting-state subcortical functional connectivity in HIV-infected patients on long-term cART
Marloes A M Janssen, Max Hinne, Ronald J Janssen, et al.
AIDS (London, England)
|
June 6, 2008
Toxic lopinavir concentrations in an HIV-1 infected patient taking herbal medications
Carolien J P Beukel van den Bout-van den, Marjolein E W Bosch, David M Burger, et al.
Antiviral Therapy
|
December 3, 2003
A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study)
David M Burger, Rob E Aarnoutse, Jeanne P Dieleman, et al.
Antimicrobial Agents and Chemotherapy
|
September 12, 2007
Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects
Manon J van der Lee, Audrey A M Blenke, Gerard A Rongen, et al.
Drug Metabolism Reviews
|
August 1, 2006
Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents
Carolien J P van den Bout-van den Beukel, Peter P Koopmans, André J A M van der Ven, et al.
AIDS (London, England)
|
June 17, 2005
Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications
Charles J L la Porte, Emile F Schippers, Marchina E van der Ende, et al.
Clinical Pharmacology and Therapeutics
|
February 2, 2002
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers
Rob E Aarnoutse, Karin J T Grintjes, Denise S C Telgt, et al.
AIDS (London, England)
|
May 6, 2008
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets
Hanneke M J Nijland, Rafaëlla F A L'homme, Gerard A Rongen, et al.
Page
of 5